Activated DCs present TAs and TAAs as MHC class I molecules to CD8+ T cells, resulting in the production of CTLs in TDLNs, which are tracked to the tumor site and eradicate tumor cells [4] (Figure 2). Here, CD8A is linked to neoplasm.